Literature DB >> 26890768

Delusions in Patients with Alzheimer's Disease: A Multidimensional Approach.

Grazia D'Onofrio1, Francesco Panza1,2, Daniele Sancarlo1, Francesco F Paris1, Leandro Cascavilla1, Antonio Mangiacotti1, Michele Lauriola1, Giulia H Paroni1, Davide Seripa1, Antonio Greco1.   

Abstract

In Alzheimer's disease (AD) patients with delusions, clinical outcomes and mortality result from a combination of psychological, biological, functional, and environmental factors. We determined the effect of delusions on mortality risk, clinical outcomes linked to comprehensive geriatric assessment (CGA), cognitive, depressive, and neuropsychiatric symptoms (NPS) in 380 consecutive AD patients with Mini-Mental State Examination, Clinical Dementia Rating scale, 15-item Geriatric Depression Scale, and Neuropsychiatric Inventory (NPI), assessing one-year mortality risk using the Multidimensional Prognostic Index (MPI). We included 121 AD patients with delusions (AD-D) and 259 AD patients without delusions (AD-noD). AD-D patients were significantly older, with higher age at onset and cognitive impairment, a more severe stage of dementia, and more depressive symptoms than AD-noD patients. Disease duration was slightly higher in AD-D patients than in those without delusions, although this difference was not statistically significant. At CGA, AD-D patients showed a higher grade of disability in basic and instrumental activities of daily living, and an increased risk of malnutrition and bedsores. The two groups of patients significantly differed in MPI score (AD-D: 0.65 versus AD-noD: 0.51, p <  0.0001) and MPI grade. AD-D patients showed also a significant higher score in NPI of the following NPS than AD-noD patients: hallucinations, agitation/aggression, depression mood, apathy, irritability/lability, aberrant motor activity, sleep disturbances, and eating disorders. Therefore, AD-D patients showed higher dementia severity, and higher impairment in cognitive and depressive symptoms, and several neuropsychiatric domains than AD-noD patients, and this appeared to be associated with higher multidimensional impairment and increased risk of mortality.

Entities:  

Keywords:  Alzheimer’s disease; Multidimensional Prognostic Index; comprehensive geriatric assessment; delusions; depressive symptoms; functional status; mortality; neuropsychiatric symptoms

Mesh:

Year:  2016        PMID: 26890768     DOI: 10.3233/JAD-150944

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  5 in total

1.  Accelerated atrophy in dopaminergic targets and medial temporo-parietal regions precedes the onset of delusions in patients with Alzheimer's disease.

Authors:  Riccardo Manca; Jose Manuel Valera-Bermejo; Annalena Venneri
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-13       Impact factor: 5.270

Review 2.  A multidimensional approach to frailty in older people.

Authors:  Alberto Pilotto; Carlo Custodero; Stefania Maggi; Maria Cristina Polidori; Nicola Veronese; Luigi Ferrucci
Journal:  Ageing Res Rev       Date:  2020-03-21       Impact factor: 10.895

3.  Hydroxytryptamine transporter gene-linked polymorphic region (5HTTLPR) is associated with delusions in Alzheimer's disease.

Authors:  Grazia D'Onofrio; Francesco Panza; Daniele Sancarlo; Michele Lauriola; Mariangela P Dagostino; Giulia Paroni; Madia Lozupone; Antonio Mangiacotti; Paola Bisceglia; Carolina Gravina; Maria Urbano; Filomena Addante; Francesco Paris; Leandro Cascavilla; Antonio Greco; Davide Seripa
Journal:  Transl Neurodegener       Date:  2019-02-01       Impact factor: 8.014

Review 4.  Behavioral and Psychiatric Symptoms of Dementia and Rate of Decline in Alzheimer's Disease.

Authors:  Reena T Gottesman; Yaakov Stern
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

Review 5.  Delusion and Delirium in Neurodegenerative Disorders: An Overlooked Relationship?

Authors:  Daniele Urso; Valentina Gnoni; Marco Filardi; Giancarlo Logroscino
Journal:  Front Psychiatry       Date:  2022-01-18       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.